Approval · Notice of Compliance 28762 · 2022
TEMODAL: Notice of Compliance 28762
Issued August 16, 2022
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 28762
- Date
- August 16, 2022
- Company
- Merck Canada IncKirkland, Quebec, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- Supplement to a New Drug Submission (SNDS), supplement
- Submission class
- Other
- Reason
- Updates to the Product Monograph. Convert the Product Monograph to the 2020 format.
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| TEMODAL | Not yet assigned | — |
Medicinal ingredients
- TEMOZOLOMIDE 5 MG per CAP
- TEMOZOLOMIDE 20 MG per CAP
- TEMOZOLOMIDE 100 MG per CAP
- TEMOZOLOMIDE 140 MG per CAP
- TEMOZOLOMIDE 250 MG per CAP